tirzepatide cvot results In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx SURPASS-CVOT — Leicester Diabetes Centre

If you have an upcoming surgery or procedure involving sedation, its critical that you inform your doctor that you are taking Mounjaro

Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly

Catch up quick : Hims and Novo briefly teamed up earlier this year to offer Wegovy at a reduced price for cash-paying patients

Through Wegovy subscription partnerships, some self-pay customers may save on their monthly costs

If someone else is giving you the injection, they may use your lower back

Hers weight loss pills, including Wegovy and Foundayo, can work for some people